Therapeutic cannabis use in 2018: where do we stand?

Lancet Psychiatry. 2019 Feb;6(2):88-89. doi: 10.1016/S2215-0366(18)30417-6.

Authors

Kevin P Hill¹, Matthew D Palastro², Tony P George³

Affiliations

¹ Division of Addiction Psychiatry, Harvard Medical School, Boston, MA, USA; Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: khill1@bidmc.harvard.edu.
² New York Medical College, Valhalla, NY, USA.
³ Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada.

PMID: 30686389
DOI: 10.1016/S2215-0366(18)30417-6

No abstract available

MeSH terms

Biomedical Research*
Cannabinoids / therapeutic use*
Cannabis*
Global Health
Government Regulation*
Humans
Nausea / drug therapy
Neurodegenerative Diseases / drug therapy
Pain / drug therapy

Substances

Cannabinoids